P. Peterlin, J. Gaschet, and T. Guillaume, FLT3 ligand plasma levels in acute myeloid leukemia, Haematologica
URL : https://hal.archives-ouvertes.fr/inserm-01993986

P. Tsapogas, C. J. Mooney, G. Brown, and A. Rolink, The Cytokine Flt3-ligand in normal and malignant hematopoiesis, Int. J. Mol. Sci, vol.18, p.6

E. Chklovskaia, P. Nowbakht, C. Nissen, A. Gratwohl, M. Bargetzi et al., Reconstitution of dendritic and natural killer-cell subsets after allogeneic stem cell transplantation: effects of endogenous flt3 ligand, Blood, vol.103, issue.10, pp.3860-3868, 2004.

H. G. Drexler, Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells, Leukemia, vol.10, issue.4, pp.588-599, 1996.

D. H. Lynch, A. Andreasen, E. Maraskovsky, J. Whitmore, R. E. Miller et al., Flt3 ligand induces tumor regression and antitumor immune responses in vivo, Nat. Med, vol.3, issue.6, pp.625-631, 1997.

J. M. Péron, C. Esche, V. M. Subbotin, C. Maliszewski, M. T. Lotze et al., FLT3-ligand administration inhibits liver metastases: role of NK cells, J. Immunol. Baltim. Md, issue.11, pp.6164-6170, 1950.

A. B. Pawlowska, S. Hashino, H. Mckenna, B. J. Weigel, P. A. Taylor et al., In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice, Blood, vol.97, issue.5, pp.1474-1482, 2001.

A. Wang, S. E. Braun, G. Sonpavde, and K. Cornetta, Antileukemic activity of Flt3 ligand in murine leukemia, Cancer Res, vol.60, issue.7, pp.1895-1900, 2000.

A. E. Morelli, M. A. Antonysamy, and T. Takayama, Microchimerism donor dendritic cells, and alloimmune reactivity in recipients of Flt3 ligand-mobilized hemopoietic cells: modulation by tacrolimus, J. Immunol. Baltim. Md, vol.165, issue.1, pp.226-237, 1950.

M. Y. Yunusov, G. E. Georges, and R. Storb, FLT3 ligand promotes engraftment of allogeneic hematopoietic stem cells without significant graft-versus-host disease, Transplantation, vol.75, issue.7, pp.933-940, 2003.

T. Teshima, P. Reddy, and K. P. Lowler, Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8 alpha(+) dendritic cells and reduces experimental acute graft-versus-host disease, Blood, vol.99, issue.5, pp.1825-1832, 2002.

. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD In, %2C+Bunworasate+U%2C+et+al.+International%2C+Multicenter +Standardization+of+Acute+Graft-versus-Host+Disease+Clinical+Data +Collection%3A >, 2019.

A. H. Filipovich, D. Weisdorf, and S. Pavletic, National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.11, issue.12, pp.945-956, 2005.

B. R. Blazar, H. J. Mckenna, A. Panoskaltsis-mortari, and P. A. Taylor, Flt3 ligand (FL) treatment of murine donors does not modify graft-versus-host disease (GVHD) but FL treatment of recipients post-bone marrow transplantation accelerates GVHD lethality, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.7, issue.4, pp.197-207, 2001.

W. Chen, A. S. Chan, A. J. Dawson, X. Liang, B. R. Blazar et al., FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function, Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant, vol.11, issue.1, pp.23-34, 2005.